High-Dose Statin Pretreatment for the Prevention of Contrast-Induced Nephropathy: A Meta-analysis

Canadian Journal of Cardiology

Volumn 27, Issue 6, 2011, Pages 851-858

  Zhang, Bu Chun ^a   Li, Wei Ming ^a   Xu, Ya Wei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; CREATININE; STATIN;

CATHETERIZATION; CONFIDENCE INTERVAL; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; HUMAN; KIDNEY DISEASE; MALE; META ANALYSIS; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK;

CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES;

EID: 82155185146     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.05.005     Document Type: Review

References (27)

1. Solomon R., Dauerman H.L. Contrast-induced acute kidney injury. Circulation 2010, 122:2451-2455.
2. Lencioni R., Fattori R., Morana G., Stacul F. Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT): a clinical problem in daily practice?. A multicenter observational study. Acta Radiol 2010, 51:741-750.
3. Reddan D., Laville M., Garovic V.D. Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings?. J Nephrol 2009, 22:333-351.
4. McCullough P.A., Adam A., Becker C.R., et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006, 98:5K-13K.
5. Khanal S., Attallah N., Smith D.E., et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005, 118:843-849.
6. Attallah N., Yassine L., Musial J., et al. The potential role of statins in contrast nephropathy. Clin Nephrol 2004, 62:273-278.
7. Ozhan H., Erden I., Ordu S., et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010, 61:711-714.
8. Acikel S., Muderrisoglu H., Yildirir A., et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis 2010, 21:750-757.
9. Xinwei J., Xianghua F., Jing Z., et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009, 104:519-524.
10. Toso A., Maioli M., Leoncini M., et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010, 105:288-292.
11. Jo S.H., Koo B.K., Park J.S., et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial: a randomized controlled study. Am Heart J 2008, 155:499.e1-499.e8.
12. Patel T.N., Shishehbor M.H., Bhatt D.L. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007, 28:664-672.
13. Toth P.P., Davidson M.H. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract 2008, 57(5 suppl):S29-S36.
14. Caixeta A., Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. Catheter Cardiovasc Interv 2010, 75(suppl 1):S15-S20.
15. Zhou X., Jin Y.Z., Wang Q., et al. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2009, 37:394-396.
16. Lin J., Hong L.-r, Qiu Y., et al. [Clinical research of atorvastatin on preventing contrast-induced nephropathy in patients underwent coronary artery CTA] [in Chinese]. Clin Med Eng 2010, 17:48-50.
17. Hua X.-p, Wu R.-x, Yang Y., et al. Prevention of contrast-induced nephropathy using high-dose atorvastatin in patients with coronary heart disease undergoing elective percutaneous coronary intervention [in Chinese]. Milit Med J South China 2010, 24:448-451.
18. Verhagen A.P., de Vet H.C., de Bie R.A., et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998, 51:1235-1241.
19. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
20. Rihal C.S., Textor S.C., Grill D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259-2264.
21. Bonetti P.O., Lerman L.O., Napoli C., et al. Statin effects beyond lipid lowering: are they clinically relevant?. Eur Heart J 2003, 24:225-248.
22. Wierzbicki A.S., Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003, 99:95-112.
23. Zager R.A., Johnson A.C., Hanson S.Y. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int 2003, 64:128-139.
24. Gueler F., Rong S., Park J.K., et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 2002, 13:2288-2298.
25. Yoshida S., Kamihata H., Nakamura S., et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol 2009, 54:192-198.
26. Zhang T., Shen L.H., Hu L.H., He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol 2011, 33:344-351.
27. Hölscher B., Heitmeyer C., Fobker M., et al. Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol 2008, 24:845-850.